Change Your Mind
DigiSep trial achieves next milestone: Over 200 sepsis patients now included
About a year ago, the recruitment phase of the trial "DigiSep - Optimization of sepsis therapy based on patient-specific digital precision diagnostics" started. Now the project, led by the Department of Anesthesiology and Intensive Care Medicine at the University Hospital Essen, has reached another important
milestone: since mid-March 2023, half of the planned 410 trial patients have been recruited. Only in February, 43 patients were added, so that the recruitment target can be reached as planned in summer 2023.
DISQVER® at the annual meeting of the DGHO in Vienna: Application of NGS-based diagnostics in Haematooncology and Medical Oncology
Infections and bloodstream infections are a major cause of complications in the therapy of oncological and hematological patients. But how can the pathogens that lead to these infections be...
Noscendo presents DISQVER® at HAI 2022, the 24th Capital Congress of the DGAI for Anaesthesiology and Intensive Care Therapy
After a pandemic-related break, the 24th Capital Congress of the German Society for Anaesthesiology & Intensive Care Medicine (DGAI) will be held again this year in presence. From September...
Press Image Gallery
Legal notice – Images in the image gallery may only be used for editorial purposes in articles about Noscendo GmbH or in articles that refer to Noscendo GmbH products. They may not be used in an offensive or defamatory manner. Images may not be altered in any way, except by cropping them to fit the layout of an article. No rights are granted to the images other than those set forth herein. By downloading an image, you accept these terms.
DISQVER STEP 1
Step 1: Sample collection. For pathogen identification with DISQVER, a single blood sample is sufficient. (Image source: Noscendo)
DISQVER STEP 2
Step 2: Sample preparation. In the laboratory, the blood samples are prepared for sequencing. (Image source: Noscendo)
DISQVER STEP 3
Step 3: Sequencing. The cell-free DNA in the blood sample is analyzed and the results are compiled in a sequencing file. (Image source: Noscendo)
DISQVER STEP 4
Step 4: Bioinformatics evaluation. Algorithms distinguish human from microbial DNA. Microbial DNA is matched against a reference database containing over 16,000 microbes – including more than 1,500 described pathogens. Bacteria, DNA viruses, parasites and fungi can thus be detected. (Image source: Noscendo)
DISQVER STEP 5
Step 5: Communication of results. The DISQVER evaluation is digitally available to the clinic and laboratory with one click – at the latest 24 hours after receipt in the laboratory. (Image source: Noscendo)
Dr. Philip Stevens,
Chief Executive Officer
Dr Philip Stevens is co-founder and CEO of Noscendo GmbH. As bioinformatician, Dr Stevens earned his PhD at the Max F. Perutz Lab (MFPL) in Vienna, a research centre attached to the University of Vienna and the Medical University of Vienna at the Vienna BioCenter. Together with Silke Grumaz and Kai Sohn, head of the Innovation Field In-vitro Diagnostics at the Fraunhofer Institute for Interfacial Engineering and Biotechnology (IGB), he developed DISQVER, a software platform for rapid pathogen identification. In 2018 the MIT Technology Review recognised Philip Stevens as ‘Innovator with the Most Social Impact 2018’, and as an ‘Innovator under 35 – Germany’. In 2019 MIT awarded him the ‘Innovator under 35 – Europe’ prize. (Image source: Noscendo)
Dr. Silke Grumaz,
Chief Scientific Officer
Dr Silke Grumaz studied biology at Hohenheim University in Stuttgart. Having completed her doctorate at the Fraunhofer Institute for Interfacial Engineering and Biotechnology (IGB), Dr Grumaz has continued to work at the Institute since 2013 researching the subject of diagnostics based on next-generation sequencing. She is co-founder and Chief Scientific Officer (CSO) of Noscendo GmbH. (Image source: Noscendo)
Dr. Peter Haug,
Chief Strategy Officer
As co-founder and Chief Strategy Officer, Dr Peter Haug is responsible within Noscendo for business development and the company’s strategic positioning. After completing his doctorate in chemistry and studying business management, he built up a contract manufacturing group with a turnover of more than EUR 250 million and 1,500 employees from plants at AstraZeneca, Bristol Myers Squibb and Roche. As a Founding Angel, since 2011 he has supported technically oriented teams from various research institutions in launching innovative start-ups in the Life Sciences sector, and particularly in diagnostics. (Image source: Noscendo)
Dr. Marcus Benz,
Chief Operating Officer
Dr Marcus Benz, COO (Image source: Noscendo)
Do you want to find out more or
Then get in touch with us!
+49 2066 50687-70